跳至主要内容
临床试验/IRCT20160809029275N4
IRCT20160809029275N4尚未招募1 期

Investigating the simultaneous effect of intrathecal and intravenous injection of autologous mesenchymal stem cells and nanocurcumin consumption in patients with Amyotrophic Lateral Sclerosis (ALS)

Mashhad University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
尚未招募
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Definite Amyotrophic Lateral Sclerosis ( ALS) patients who have been diagnosed with ALS by a specialist neurologist and have The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale-R (ALSFRS-R) of 31 to 46
  • Patients who have been treated with a define dose of Rilozule for the past three months.
  • Patients who have entered the study by filling the informed consent form.
  • Patients who do not use ventilators
  • Patients who do not have any other chronic diseases that may interfere with the study.

排除标准

  • The presence of specific autoimmune and underlying diseases, cancer and any malignancy.
  • Simultaneous participation in other clinical trials.

研究者

相似试验